Acelity said today it tapped R. Eckert as its new prez & CEO, succeeding Joseph Woody who is stepping away from Acelity following the company’s divestiture of its LifeCell division earlier this year.
Eckert previously served as CEO of health information tech company TriZetto Corp, and has led 5 other companies including CRC Health Group, Eclipsys Copr, ADAC Labs and Valence Healthcare. He currently serves as board chair at Varian Medical (NYSE:VAR) and is a board member for Becton Dickinson & Co. (NYSE:BDX).
“We have a proven and experienced leader at the helm as we embark on a promising new phase in the transformation of Acelity. Andy brings a significant set of expertise and experience from across the healthcare and technology sectors and will be a tremendous addition to the team as we concentrate on developing and expanding our industry-leading portfolio of advanced wound therapies. On behalf of the Acelity Board of Directors, I would like to thank Joe Woody for his leadership of the company since 2011. Joe introduced Acelity to the marketplace by successfully leading the integration of KCI, Systagenix and LifeCell to create a global leader in medical device and technology and oversaw a period of significant expansion in new product development and therapy adoption. With the successful divestiture of LifeCell, we look ahead to an exciting new chapter of growth and opportunity for Acelity,” Acelity board chair Buddy Gumina said in a prepared statement.
“This is a remarkable time for Acelity as we navigate the complex evolution of healthcare delivery in markets around the world. I welcome the challenge and look forward to leading Acelity’s talented team of more than 4,800 colleagues worldwide at this point in the company’s progression. We have an important opportunity to realize growth by embracing the shift to value-based care and delivering to patients and customers innovative products and therapies that address the burdens of treating chronic and acute wounds,” Eckert said in prepared remarks.
“I am proud of our achievements at Acelity during the past several years. As I reflect on what we accomplished, perhaps most important to me is the number of patients we are able to now reach with the Acelity portfolio. Looking ahead, I know that the passion and drive of everyone at Acelity to improve the lives of people around the world will lead to innovative new solutions in advanced wound therapy and as an ongoing shareholder of Acelity, I am very excited about the company’s next phase of growth,” former CEO Woody said in a press release.
Digital health startup InfoBionic said this week it named former Monarch Medical Systems CEO Stuart Long as its new chief executive officer.
Prior to his time at Monarch, McHenry operated as global chief marketing and sales officer for CapsuleTech, which was acquired by Qualcomm (NSDQ:QCOM) subsidiary Qualcomm Life. He has also held positions at Royal Philips (NYSE:PHG), InfoBionic said.
“In my experience, when you empower the hands-on healthcare provider, you have the opportunity to derive the best possible outcome for the patient. InfoBionic’s founding was predicated around improving patient care by implementing disruptive solutions in today’s modern healthcare market. I look forward to building upon my years of service within the healthcare community, and to scaling this innovative platform to support the evolving remote cardiac monitoring needs of the future. The InfoBionic team has done a remarkable job understanding customer needs in the arrhythmia detection and monitoring arena and developing a truly innovative product and business model to address those needs. The InfoBionic platform is uniquely positioned to empower the healthcare practitioner as it turns existing models upside down and uniquely addresses the core issues of quality, functionality, reliability and reimbursement,” Long said in a prepared statement.
Healthcare company Merz said this week it appointed Bob Rhatigan as its new prez and CEO of Merz North America, and Patrick Urban as its CCO.
“The global leadership team and I have great confidence that Bob Rhatigan has the strategic vision, extensive industry knowledge and operational experience that is needed to drive growth and lead Merz North America to continued success. He has a proven track record of accomplishments and unparalleled experience that bring great benefit to our company’s aesthetics and neurotoxins portfolio. Bob also brings a personal style that is fully aligned with our values and culture, making him a natural fit for the team,” Merz Pharma CEO Philip Burchard said in a prepared statement.
“I am honored and excited to lead the Merz North America team to an even higher level of achievement and ensure a successful future for the organization. We have a well-rounded and strong portfolio in which I see clear potential. I am fortunate to work with a deeply experienced senior leadership team as we continue to target innovative approaches and growth opportunities with a strategic focus on our aesthetics and neurotoxins business. We will remain committed to being a trusted partner for our customers to provide long-term value as well as meet the evolving needs of our patients,” Rhatigan said in a press release.
The London-based company said it has initiated an external search for a replacement, and that Sehgal will continue as CFO and will support the transition.
“Vivid has been the company’s CFO since its inception in October 2015 and has been an integral part of our Executive Leadership team. His leadership, insights and guidance have been instrumental in building a strong team, while establishing financial disciplines across the portfolio. His presence, knowledge and leadership will be important through the transition period. We wish to thank him for his many contributions in helping to position the company for sustainable growth,” CEO Damien McDonald said in a prepared statement.
“I have a number of things I wish to do, not the least of which will be spending more time with family and pursuing personal interests. I am very proud of what we have accomplished for our employees and shareowners in a short time as a new public company. We made progress in critical areas, including achieving merger-related synergies, restructuring, capital formation, cost controls and building a sustainable tax strategy. I remain fully committed to helping Damien and the LivaNova team with this important transition,” Sehgal said in a press release.
McHenry previously served as senior director of global operations integration and site optimization at St. Jude, Dynatronics said.
“Cyndi’s experience in manufacturing, distribution, purchasing and integration brings significant depth to the Dynatronics’ management team. Given Cyndi’s extensive background across all areas of production and change management, as well as her experience at St. Jude Medical for nearly 20 years, I am confident in her ability to lead our operations. I believe she will be a strong leader in all aspects of our manufacturing, distribution and purchasing. I look forward to the ideas and perspectives she will bring to Dynatronics,” CEO Kelvyn Cullimore said in a press release.
“I am very pleased to join Dynatronics. This is a company with a great reputation and momentum in the physical medicine industry. I am excited to join the management team and to contribute to the success of the business as we continue to evolve into a profitable and growing company,” McHenry said in a prepared statement.
- Staar Surgical names Andrews as interim CFO
- Titan Medical appoints Jensen as Reg, QA head
- Iradimed taps McCreery as COO
- AdvaStim enlists ex-Integer CTO Cintra
- AdvaMed adds Rotation Med’s Shadan to board
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.